Home Samsung merger to drive growth in biopharmaceutical business
 

Keywords :   


Samsung merger to drive growth in biopharmaceutical business

2015-07-20 13:25:34| Semiconductors - Topix.net

Boosted by the successful merger of Samsung C&T and Cheil Industries last week, Samsung Group is geared to step up its efforts to expand and develop its biopharmaceutical business, seen by the group as a future growth engine. The $8 billion merger has tightened the group's grip on Samsung BioLogics, the conglomerate's biopharmaceutical business unit.

Tags: business drive growth samsung

Category:Electronics and Electrical

Latest from this category

All news

»
27.11Washington Corner | November 2024
27.11
27.11MTG 4
27.1119
27.11
27.11Y-3
27.11
27.1125th PSA10
More »